Compare SLVM & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLVM | NVAX |
|---|---|---|
| Founded | 1898 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2021 | 1996 |
| Metric | SLVM | NVAX |
|---|---|---|
| Price | $38.90 | $9.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $54.00 | $11.33 |
| AVG Volume (30 Days) | 279.3K | ★ 4.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ 3.24 | 2.58 |
| Revenue | ★ $3,351,000,000.00 | $1,123,479,000.00 |
| Revenue This Year | $0.98 | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | $12.27 | ★ $3.89 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $37.52 | $5.01 |
| 52 Week High | $68.76 | $11.85 |
| Indicator | SLVM | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 24.93 | 47.45 |
| Support Level | $38.06 | $9.14 |
| Resistance Level | $46.59 | $10.42 |
| Average True Range (ATR) | 1.58 | 0.60 |
| MACD | -0.48 | -0.10 |
| Stochastic Oscillator | 1.62 | 19.40 |
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.